...
首页> 外文期刊>American Journal of Tropical Medicine and Hygiene >Azithromycin/Chloroquine Combination Does Not Increase Cardiac Instability despite an Increase in Monophasic Action Potential Duration in the Anesthetized Guinea Pig
【24h】

Azithromycin/Chloroquine Combination Does Not Increase Cardiac Instability despite an Increase in Monophasic Action Potential Duration in the Anesthetized Guinea Pig

机译:尽管在麻醉的豚鼠中单相动作电位持续时间增加,但阿奇霉素/氯喹联合使用不会增加心脏的不稳定性

获取原文
获取原文并翻译 | 示例
           

摘要

Prolongation of the electrocardiogram QT interval by some, but not all drugs, has been associated with increased incidence of sudden cardiac death. Current preclinical regulatory assays cannot discriminate the arrhythmia liability of these drugs. Consequently, many new medications that prolong the QT interval are not developed despite their potential therapeutic benefit. Alternans (action potential duration alternations) is a measure of cardiac instability in humans and animals associated with the onset of ventricular fibrillation. Due to potential arrhythmia risk from observed QT prolongation, alternans was assessed in the anesthetized guinea pig after azithromycin or chloroquine alone and after combination treatment at clinically relevant concentrations proposed for the management of malaria. Chloroquine alone, but not azithromycin, caused a profound increase in action potential duration but with only minimal effects on alternans (~10 ms). Azithromycin alone and in combination with chloroquine showed no increase in alternans beyond vehicle baseline responses indicating no additional arrhythmia liability.
机译:某些(但不是全部)药物延长了心电图QT间隔,这与心源性猝死的发生率增加有关。 当前的临床前监管测定法 不能区分这些药物的心律失常责任。 因此,尽管它们具有潜在的发展潜力,但许多延长QT间隔时间的新药物并未得到开发。 Alternans(动作电位持续时间交替)是一种衡量 与心室纤颤发作有关的人和动物心脏不稳定性的指标。由于观察到的QT延长可能导致心律失常的风险,因此在单独使用阿奇霉素或氯喹的麻醉后的 麻醉的豚鼠中评估了联蛋白的临床疗效。建议用于管理疟疾的相关 浓度。单独使用氯喹 而不引起阿奇霉素引起动作 电位持续时间的大幅增加,但对交替糖 的影响很小(〜10 ms)。单独使用阿奇霉素和与氯喹联合使用时,显示出超出车辆基线反应的交替糖没有增加 ,表明没有额外的心律失常责任。

著录项

  • 来源
  • 作者单位

    Pfizer Global Research and Development, Departments of Translationaland Molecular Medicine, Safety Pharmacology, Drug Metabolismand Biostatistics, Groton, Connecticut;

    Pfizer Global Research and Development, Departments of Translationaland Molecular Medicine, Safety Pharmacology, Drug Metabolismand Biostatistics, Groton, Connecticut;

    Pfizer Global Research and Development, Departments of Translationaland Molecular Medicine, Safety Pharmacology, Drug Metabolismand Biostatistics, Groton, Connecticut;

    Pfizer Global Research and Development, Departments of Translationaland Molecular Medicine, Safety Pharmacology, Drug Metabolismand Biostatistics, Groton, Connecticut;

    Pfizer Global Research and Development, Departments of Translationaland Molecular Medicine, Safety Pharmacology, Drug Metabolismand Biostatistics, Groton, Connecticut;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号